SCHEMBL1337225

SCHEMBL1337225

Cn1c(=O)c(-c2ccc(Cl)cc2F)cc2c3ccccc3n(C)c21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 3/20 0.42
▸ KDM4E B2RXH2 3/20 0.42
▸ ALDH1A1 P00352 2/20 0.42
▸ GAA P10253 2/20 0.42
▸ HSD17B10 Q99714 1/20 0.42
▸ HSD11B1 P28845 2/20 0.40
▸ GRM2 Q14416 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ PSEN1 P49768 1/20 0.39
▸ PSEN2 P49810 1/20 0.39
▸ APH1B Q8WW43 1/20 0.39
▸ NCSTN Q92542 1/20 0.39
▸ APH1A Q96BI3 1/20 0.39
▸ PSENEN Q9NZ42 1/20 0.39
▸ HSP90AA1 P07900 1/20 0.39
▸ IDO1 P14902 1/20 0.39
▸ LMNA P02545 2/20 0.38
▸ MAPT P10636 2/20 0.38
▸ ALOX15 P16050 1/20 0.38
▸ TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1338090 0.87 KDM4E (0.52) HPGDKDM4EALDH1A1GAAHSD17B10
SCHEMBL1338652 0.82 ATM (0.47) HPGDKDM4EALDH1A1GAAHSD17B10
SCHEMBL1337392 0.82 HSD17B10 (0.46) HPGDKDM4EALDH1A1GAAHSD17B10
SCHEMBL1338688 0.82 GABRA1 (0.41) KDM4EGRM2MAPTCYP2C9TAS2R14
SCHEMBL4761085 0.80 GABRA1 (0.38) KDM4EGRM2L3MBTL1MEN1POLB
SCHEMBL1338390 0.79 L3MBTL1 (0.43) L3MBTL1PSEN1PSEN2APH1BNCSTN
SCHEMBL1336997 0.76 MAPK14 (0.49) HPGDKDM4EALDH1A1HSD17B10HSP90AA1
SCHEMBL1337357 0.76 ALDH1A1 (0.50) HPGDKDM4EALDH1A1GAAHSD17B10
SCHEMBL3866299 0.75 HSD17B10 (0.44) KDM4EALDH1A1HSD17B10L3MBTL1LMNA
SCHEMBL4761086 0.75 EGFR (0.43) HPGDKDM4EALDH1A1GAAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063061-B2 6-(2-amino-1,3-thiazol-4-yl)-3-(2,4-dichlorophenyl)-1-methyl-1,9-dihydro-2H-pyrido[2,3-b]indol-2-one; affinity for GABAA-receptor-associated omega modulatory sites SANOFI-AVENTIS (FR) 2011-11-22 — — US disclosed
EP-1940840-B1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2010-07-21 — — EP disclosed
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof SANOFI-AVENTIS (FR) 2008-10-23 — — US disclosed
EP-1940840-A1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2008-07-09 — — EP disclosed
WO-2007045758-A1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2007-04-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof CYP11B2, CYP11B1, CYP2D6 HPGD 203/4885KDM4E 1908/4885ALDH1A1 283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback